Download MendeleyConformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations.
Chen, H., Lai, M., Zhang, T., Chen, Y., Tong, L., Zhu, S., Zhou, Y., Ren, X., Ding, J., Xie, H., Lu, X., Ding, K.(2022) J Med Chem 65: 6840-6858
- PubMed: 35446588
- DOI: https://doi.org/10.1021/acs.jmedchem.2c00168
- Primary Citation of Related Structures:
7VRA, 7VRE - PubMed Abstract:
Tertiary C797S mutation of epidermal growth factor receptor (EGFR)-mediated resistance in non-small-cell-lung-cancer (NSCLC) patients is still an unmet clinical need. Several classes of adenosine 5'-triphosphate-competitive or allosteric EGFR T790M/C797S inhibitors and degraders have been developed, but none of them have received approval from the regulatory agencies. Herein, we report the structure-based design of conformational constrained 4-(1-ethylsufonyl-3-indolyl)-2-phenylaminopyrimidines as new EGFR T790M/C797S inhibitors by using a macrocyclization strategy. Representative compound 18j potently inhibited EGFR 19del/T790M/C797S and EGFR L858R/T790M/C797S mutants with IC 50 values of 15.8 and 23.6 nM and suppressed Ba/F3-EGFR L858R/T790M/C797S and Ba/F3-EGFR 19del/T790M/C797S cells with IC 50 values of 0.036 and 0.052 μM, respectively, which is 10-20-fold more potent than brigatinib. 18j also potently inhibited the EGFR 19del/T790M/C797S -mutated PC-9-OR NSCLC cell proliferation with an IC 50 value of 0.644 μM but was less potent for parental Ba/F3 and A431 cells. This study provides a new lead compound for drug discovery to combat EGFR C797S -mediated resistance in NSCLC patients.
Organizational Affiliation:
International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy and the 1st Affiliated Hospital (Huaqiao Hospital), Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China.
